Clinical Trial Update: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing Retatrutide (LY3437943) to Tirzepatide (LY3298176) in adults with obesity, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Retatrutide (retatrutide)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING